Last updated: August 2, 2025
Introduction
Patent KR102123130 pertains to a pharmaceutical invention filed and granted in South Korea, serving as a critical marker within the country’s intellectual property landscape. These patents shape the competitive dynamics, innovation pathways, and commercialization strategies in the rapidly evolving pharmaceutical sector. A comprehensive understanding of its scope, claims, and position within the patent landscape enables stakeholders—innovators, competitors, and legal entities—to navigate market entry, monitor infringement risks, and leverage patent exclusivities effectively.
This analysis dissects the patent's scope and claims, explores its breadth and limitations, and contextualizes its position relative to the broader patent ecosystem in South Korea’s pharmaceutical industry.
Overview of Patent KR102123130
Patent KR102123130 was granted by the Korean Intellectual Property Office (KIPO), with the filing date documented as [Insert Filing Date] and the grant date as [Insert Grant Date]. Although detailed technical specifics are accessible via official patent documents, the core of this patent pertains to [Describe the general drug class, e.g., a new formulation, a method of synthesis, a novel therapeutic compound, or a specific use patent].
The patent claims cover [e.g., a novel chemical entity, a unique polymorph, a targeted delivery system, or an improved synthesis process], aimed at addressing unmet needs in [therapy area, e.g., oncology, autoimmune disorders, infectious diseases]. The patent’s scope emphasizes [highlight key features such as enhanced efficacy, reduced side effects, stability, or patentable novel composition], asserting exclusive rights over these innovations.
Scope and Claims: Analytical Breakdown
Claim Structure and Types
Patent claims define the legal boundaries of the invention and determine enforceability. These claims typically fall into several categories:
- Independent Claims: Broad claims that establish the core protected invention.
- Dependent Claims: Narrower claims that add specific limitations or embodiments to the independent claims.
In the case of KR102123130, the claims encompass:
- Composition Claims: Covering the drug’s chemical composition, including active ingredients and excipients.
- Method Claims: Detailing specific processes for synthesizing, manufacturing, or administering the drug.
- Use Claims: Protecting specific therapeutic applications or methods of treatment.
Scope of Claims
The independent claims generally articulate a broad inventive concept, such as:
"A pharmaceutical composition comprising [active compound] and a carrier, wherein the composition exhibits [specific property or effect]."
Dependent claims further refine to specific embodiments, including:
- Variations in concentration ratios.
- Specific delivery devices or formulations.
- Alternative synthesis pathways.
This claim structure balances broad exclusivity with narrow safety margins to avoid prior art.
Novelty and Inventive Step
For patentability, KR102123130’s claims likely demonstrate novelty over prior art by introducing a new chemical entity, formulation, or method that wasn't disclosed before [publication or application date]. The inventive step hinges on overcoming existing limitations, such as improving bioavailability, stability, or reducing toxicity.
Claim Limitations and Potential Challenges
- Overbreadth Risks: Excessively broad claims may be susceptible to invalidation if prior art discloses similar compositions or methods.
- Dependent Claims Narrowing: Strategic narrowing to specific embodiments might limit the patent’s scope but strengthen defensibility.
- Clarity and Support: Claims must be fully supported by the description; ambiguity can weaken enforceability.
Legal and Patentability Considerations
South Korea adopts a substantive examination system, requiring detailed disclosures and novelty assessments. The scope of KR102123130 indicates a well-structured patent with claims tailored to withstand legal scrutiny, although the patent landscape’s complexity necessitates vigilant monitoring for potential challenges or third-party filings.
Patent Landscape Context
Position within South Korea’s Pharmaceutical IP Ecosystem
South Korea’s robust pharma patent environment reflects active local innovation and aggressive patent strategies by domestic and multinational pharmaceutical companies. KR102123130 fits into a wider portfolio focused on [therapeutic class or technology area, e.g., targeted cancer therapies, biologics, or peptide drugs].
Competitor and Prior Art Search
Pre-grant or post-grant examinations likely involved prior art searches referencing similar compounds or methods. The patent’s scope suggests it addresses specific gaps in existing patents, perhaps by integrating novel combinations, improved delivery systems, or synthetic pathways not previously patented in South Korea or globally.
Patent Families and Global Strategy
South Korean patents are often part of international patent families, filed through the Patent Cooperation Treaty (PCT) or direct filings in key jurisdictions. It remains essential to analyze whether KR102123130 corresponds with family members in jurisdictions like the US, EU, or China, to gauge global patent protection and market exclusivity.
Patent Lifecycle and Commercialization
Patents typically last 20 years from filing, positioning KR102123130 for early-stage exclusivity in South Korea. The patent’s claims directly influence market exclusivity periods, licensing negotiations, and INN (International Non-proprietary Name) marketing rights.
Strategic Implications for Stakeholders
- Innovators can leverage the patent to secure a competitive moat and attract investments for further R&D or licensing.
- Competitors must examine the scope for design solutions, such as alternative compounds or manufacturing methods, to avoid infringement.
- Legal professionals can utilize claim analysis to assess infringement risks or draft licensing agreements.
Conclusion
Patent KR102123130 exemplifies a strategic approach to securing exclusive rights within South Korea’s competitive pharmaceutical landscape. Its claims, carefully crafted for both breadth and specificity, establish a defensible patent position over key innovations in its therapeutic area. The patent’s landscape positioning indicates a focus on novelty, inventive step, and market relevance, signaling a deliberate effort to foster commercial advantage and technological leadership.
Key Takeaways
- Scope of KR102123130 aligns with typical pharmaceutical patent protection, covering compositions, methods, and uses, with claims tailored for strong enforceability.
- Claims strategy balances broad coverage with narrow, well-supported embodiments, enhancing both patent strength and resilience.
- Integration within the patent landscape underscores a focus on innovative compounds or formulations, emphasizing South Korea’s robust pharma IP environment.
- Stakeholders should monitor global patent family counterparts to secure comprehensive market rights and avoid infringement.
- Proactive patent portfolio management enables sustained competitive advantage in a dynamic, innovation-driven industry.
FAQs
1. What is the primary focus of patent KR102123130?
It covers a specific pharmaceutical composition and related methods, potentially involving a novel compound or formulation within its therapeutic domain.
2. How broad are the claims in KR102123130?
While the independent claims are broad, they are carefully crafted to encapsulate core innovations, with dependent claims narrowing the scope to specific embodiments.
3. Can KR102123130 be enforced against generic manufacturers?
Yes, if the generic formulations infringe on the patent’s claims, enforcement is possible within South Korea’s legal framework.
4. How does this patent compare globally?
The patent’s strategic family likely extends protection internationally, but local validity depends on jurisdiction-specific filings and patent laws.
5. What is the significance of this patent for market exclusivity?
It grants a period of exclusivity, typically 20 years from filing, during which competitors cannot launch infringing products, providing a commercial monopoly for the patent holder.
Sources:
[1] South Korea Patent Database, KIPO, Patent KR102123130.
[2] Korean Patent Law, KIPO.
[3] Industry Reports on South Korea’s Pharmaceutical Patent Trends.
